Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in ugandan infants

AIDS Research and Human Retroviruses

Volumn 25, Issue 7, 2009, Pages 657-663

  Church, Jessica D ^a   Huang, Wei ^b   Parkin, Neil ^b   Marlowe, Natalia ^c   Guay, Laura A ^a   Omer, Saad B ^d   Musoke, Philippa ^e   Jackson, J Brooks ^a   Eshleman, Susan H ^a,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c School of Public Health ^*

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e MAKERERE UNIVERSITY   (Uganda)

^f DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTERMETHOD COMPARISON; LABORATORY TEST; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; UGANDA;

EID: 70349224307     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0235     Document Type: Article

References (31)

1. McConnell MS, Stringer JS, Kourtis AP, Weidle PJ, and Eshleman SH: Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: Does development of resistance matter? Am J Obstet Gynecol 2007;197:S56-S63.
2. Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, et al.: Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: An analysis of three randomised controlled trials. Lancet 2008;372:300-313.
3. Church JD, Omer SB, Guay LA, et al.: Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV-infected despite receiving single dose (SD) nevirapine (NVP) vs. SD NVP plus daily NVP up to 6-weeks of age to prevent HIV vertical transmission. J Infect Dis 2008;198(7):1075-1082.
4. Eshleman SH, Mracna M, Guay LA, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957.
5. Martinson NA, Morris L, Gray G, et al.: Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153.
6. Moorthy A, Gupta A, Sastry J, et al.: Nevirapine resistance and breast-milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C infected infants. PloS ONE 2009;4:e4096.
7. Lockman S, Shapiro RL, Smeaton LM, et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-147.
8. Johnson JA, Li JF, Wei X, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008;5:e158.
9. Van Laethem K, De Munter P, Schrooten Y, et al.: No response to first-line tenofovir +lamivudine +efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 2007;39:43-47.
10. Mellors J, Palmer S, Nissley D, et al.: Low-frequency NNRTI-resistant variants contribute to failure of efavirenzcontaining regimens. 11th Conference on Retroviruses and Opportunistic Infections 2004, San Francisco, CA, February 8-11, 2004. Abstract #39.
11. Coovadia A, Hunt G, Abrams EJ, et al.: Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reversetranscriptase inhibitor-based therapy. Clin Infect Dis 2009; Jan. 9 [Epub ahead of print].
12. Eshleman SH, Crutcher G, Petrauskene O, et al.: Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol 2005;43:813-817.
13. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44: 920-928.
14. Hellmann N, Johnson P, and Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSenseHIV. Antiviral Ther 1999:4(Suppl. 1):34.
15. Shi C, Eshleman SH, Jones D, et al.: LigAmp: Sensitive detection of single nucleotide differences. Nat Methods 2004;1:141-147.
16. Flys T, Nissley DV, Claasen CW, et al.: Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005;192:24-29.
17. Church JD, Towler WI, Hoover DR, et al.: Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants. AIDS Res Hum Retroviruses 2008;24:595-605.
18. Church JD, Jones D, Flys T, et al.: Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006;8:430-432.
19. Palmer S, Kearney M, Maldarelli F, et al.: Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005;43:406-413.
20. Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, and Alcami J: A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol 2007;79: 127-137.
21. Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, and Lopez-Galindez C: In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 2002;83:93-101.
22. Zhang H, Zhou Y, Alcock C, et al.: Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004;78:1718-1729.
23. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, and Petropoulos CJ: Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr 2002;31:128-136.
24. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children: Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. http:==aidsinfo.nih.gov=contentfiles= PediatricGuidelines.pdf. Accessed 4=2008.
25. Eshleman SH, Guay LA, Mwatha A, et al.: Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004;35:126-130. (Pubitemid 38133734)
26. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, and Petropoulos CJ: Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:437-443.
27. Leigh Brown AJ, Precious HM, Whitcomb JM, et al.: Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000;74:10269-10273.
28. Pandit A, Mackay WG, Steel C, van Loon AM, and Schuurman R: HIV-1 drug resistance genotyping quality assessment : Results of the ENVA7 Genotyping Proficiency Programme. J Clin Virol 2008;43:401-406.
29. Schuurman R, Brambilla D, de Groot T, et al.: Underestimation of HIV type 1 drug resistance mutations: Results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002;18:243-248.
30. Flys TS, Donnell D, Mwatha A, et al.: Persistence of K103Ncontaining HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007;195:711-715.
31. Flys TS, Chen S, Jones DC, et al.: Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single dose nevirapine in women with HIV-1 subtypes A, C and D. J Acquir Immune Defic Syndr 2006;42:61-63.